Companies / TRI

TRIVARX LTD

ASX:TRIHealth Care Equipment & Services
1.15B shares on issueASX (delayed) · as of 28 July 2026$0.017price · delayed$19.6Mmarket cap · indicative
C
Dilution grade

Share count grew 155% in 24 months; 4 cash raises in 24 months; runway 4–8 quarters

Cash runway5.0 quarters of funding
Share-count growth (24m)154.9%
Raise cadence (24m)4 cash raises
Options & rights overhang18.3% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

TRIVARX LTD's ordinary share count grew 154.9% between July 2024 and December 2025, to 1.15B shares. The company raised capital four times in that 24‑month window for total disclosed proceeds of A$6.6M, most recently raising A$4.2M in October 2025. Options and rights on issue could convert into 211M new shares, equal to 18.3% of the current share count, with 0% in the money at present and the nearest expiry in May 2027. At the June 2026 quarter TRIVARX reported A$2.3M in cash, equivalent to 5.0 quarters of cover. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
18.3%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
5.0 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 1.15B per ASX (delayed) (28 July 2026).
0.61B0.81B1.01BDec 24Sept 25July 26Cash raise · 6 Oct 2025Cash raise · 25 Mar 2025Cash raise · 12 Mar 2025

Cash runway

5.0 qtrs
More than four quarters of funding at the recent spend rate.
$2.3M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
18 Dec 20253G · unquotedTRI : ORDINARY FULLY PAID716.0MAppendix 3G
18 Dec 20252A · quoted issueTRI : ORDINARY FULLY PAID1.15BAppendix 2A
18 Dec 20253G · unquotedTRI : ORDINARY FULLY PAID716.0MAppendix 3G
9 Dec 20253H · cancellationTRI : ORDINARY FULLY PAID716.0MAppendix 3H
2 Dec 20252A · quoted issueTRI : ORDINARY FULLY PAID716.0MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

4 cash raises in the last 24 months · 1 in the last 12 months

$4.2M
Capital raise
6 Oct 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

18.3%
Total overhang · of current shares
0.0%
In the money · at current price
211.1M
Potential new shares
May 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
19 Dec 2025Christopher NtoumenopoulosOther81.3M—$498k3Y notice
19 Dec 2025David TrimboliBuy6.3M—$50k3Y notice
2 Dec 2025David TrimboliOther3.3M7.0M$72k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

28 July 2026$PJune 2026 Quarterly Activities Report and Appendix 4C
15 July 2026$PStabl-Im clinical trial supply milestone achieved
24 June 2026Investor Presentation - Stabl-Im program
26 May 2026Change of Registered Office Address
21 May 2026$PCRO Engaged to Advance Stabl-Im Phase 1 Trial
29 Apr 2026$PMarch 2026 Quarterly Activities Report and Appendix 4C
28 Apr 2026$PDr Danielle Meyrick appointed as CEO
4 Mar 2026Key management changes
24 Feb 2026$PAppendix 4D & Half-Year Financial Report to 31 December 2025
29 Jan 2026$PDecember 2025 Quarterly Activities Report and Appendix 4C
1 Jan 2026Final Director's Interest Notice - John Mathias
23 Dec 2025Ceasing to be a substantial holder
22 Dec 2025Becoming a substantial holder - Daniel Tillett
22 Dec 2025Second-tranche placement funding completed
18 Dec 2025Change of Director's Interest Notice - David Trimboli
18 Dec 2025Change of Director's Interest Notice - Chris Ntoumenopoulos
18 Dec 2025Cleansing Notice
18 Dec 2025Notification regarding unquoted securities - TRI
18 Dec 2025Application for quotation of securities - TRI
18 Dec 2025Notification regarding unquoted securities - TRI

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.